Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021, ending September 30, 2021.

The event will cover recent business highlights and can be accessed by calling 1 (833) 519-1307 (U.S.) or +1 (914) 800-3873 (international) with conference ID 1235955. The live webcast will be available on the company's website, with a replay archived afterward.

Imara focuses on developing therapeutics for rare genetic disorders related to hemoglobin, including sickle cell disease and beta-thalassemia.

Positive

• Upcoming conference call to discuss financial results, potentially providing clarity on operational performance.
• Continued development of therapeutics like tovinontrine (IMR-687) and IMR-261, targeting serious diseases.

Negative

• None.

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 1235955. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for sickle cell disease and beta-thalassemia and preclinical development for HFpEF. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2 (Nrf2). For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What are Imara's financial results for Q3 2021?

The financial results for Q3 2021 will be discussed during the conference call on November 9, 2021.

When is Imara's conference call to discuss business highlights?

Imara's conference call is scheduled for November 9, 2021, at 8:30 a.m. ET.

What is the focus of Imara's clinical development?

Imara focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia.